AstraZeneca’s Brilique Triumphs As First Drug Through Germany’s New Pricing Process
09:33 EDT 1 Jun 2012 | Elsevier Business Intelligence
Following negotiations, AstraZeneca’s clot buster Brilique has been awarded a price that has pleased both the manufacturer and health insurers – but industry as a whole remains skeptical of the system.
Original Article: AstraZeneca’s Brilique Triumphs As First Drug Through Germany’s New Pricing Process
More From BioPortfolio on "AstraZeneca’s Brilique Triumphs As First Drug Through Germany’s New Pricing Process"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
